Attached files
| file | filename |
|---|---|
| EX-16.1 - LETTER FROM STAN JEONG-HA LEE, CPA - JINZANGHUANG TIBET PHARMACEUTICALS, INC. | ex16-1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: December 5, 2012
|
JINZANGHUANG TIBET PHARMACEUTICALS, INC.
|
||
|
(Exact name of registrant as specified in its charter)
|
||
|
Delaware
|
0-53254
|
26-2443288
|
|
(State of other jurisdiction of
|
(Commission File No.)
|
(IRS Employer
|
|
incorporation or organization
|
Identification No.)
|
|
|
Leling Economic Development Zone, Kaiyuan East Blvd., Dezhou,
Shandong Province, P.R. China 253600
|
||
|
(Address of principal executive offices) (Zip Code)
|
||
|
86-534-2111-962
|
||
|
(Registrant’s telephone number including area code)
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 4.01 Change in Registrant’s Certifying Accountant
On December 5, 2012 the Board of Directors of Jinzanghuang Tibet Pharmaceuticals, Inc. approved the dismissal of Stan Jeong-Ha Lee, CPA from his position as the principal independent accountant for Jinzanghuang Tibet Pharmaceuticals.
The Board of Directors engaged Stan Jeong-Ha Lee, CPA as principal independent accountant on June 21, 2012. The audit report of Stan J.H. Lee, CPA on Jinzanghuang Tibet Pharmaceutical’s financial statements for the fiscal year ended June 30, 2012 did not contain an adverse opinion or disclaimer of opinion or qualification or modification. Stan Jeong-Ha Lee, CPA did not, during the applicable periods, advise Jinzanghuang Tibet Pharmaceuticals of any of the enumerated items described in Item 304(a)(1)(iv) of Regulation S-K.
Jinzanghuang Tibet Pharmaceuticals and Stan Jeong-Ha Lee, CPA have not, during Jinzanghuang Tibet Pharmaceuticals’ most recent fiscal year or any subsequent period through the date of dismissal, had any disagreement on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to Stan Jeong-Ha Lee, CPA’s satisfaction, would have caused Stan Jeong-Ha Lee, CPA to make reference to the subject matter of the disagreement in connection with his reports.
Jinzanghuang Tibet Pharmaceuticals has requested Stan Jeong-Ha Lee, CPA to furnish a letter addressed to the Securities Exchange Commission stating whether or not Stan Jeong-Ha Lee, CPA agrees with the statements in this Form 8-K. A copy of the letter is filed as an exhibit to this 8-K.
On December 5, 2012 Jinzanghuang Tibet Pharmaceuticals retained KCCW Accountancy Corp. to audit Jinzanghuang Tibet Pharmaceuticals’ financial statements for the year ended June 30, 2013. At no time during the two most recent fiscal years and the subsequent interim period through December 5, 2012, the date of the engagement, did Jinzanghuang Tibet Pharmaceuticals consult with KCCW Accountancy Corp. regarding any matter of the sort described above with reference to Stan Jeong-Ha Lee, CPA, any issue relating to the financial statements of Jinzanghuang Tibet Pharmaceuticals, or the type of audit opinion that might be rendered for
Jinzanghuang Tibet Pharmaceuticals.
Item 9.01 Financial Statements and Exhibits
Exhibits
|
16.1
|
Letter from Stan Jeong-Ha Lee, CPA
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
JINZANGHUANG TIBET PHARMACEUTICALS, INC.
|
||
|
Dated: December 6, 2012
|
By:/s/ Xue Bangyi
|
|
|
Xue Bangyi
|
||
|
Chief Executive Officer
|